NewsBenzingaKazia Therapeutics Says Two Abstracts Highlighting Paxalisib Tumor And Immune Reprogramming Research Accepted For Poster Presentation At 2026 San Antonio Breast Cancer Symposium Kazia Therapeutics Says Two Abstracts Highlighting Paxalisib Tumor And Immune Reprogramming Research Accepted For Poster Presentation At 2026 San Antonio Breast Cancer Symposium Benzinga 2026.11.02 12:12 (GMT+0) Open on Benzinga Other news POET Technologies Gets a New CFO Ahead of Its Nov. 16 Earnings Report Wells Fargo Maintains Overweight on LyondellBasell Industries, Raises Price Target to $76 Guggenheim Maintains Buy on First Solar, Lowers Price Target to $297 Wells Fargo Maintains Equal-Weight on nVent Electric, Raises Price Target to $190 Guggenheim Maintains Buy on Regeneron Pharmaceuticals, Raises Price Target to $1100 Foreign Media: Apple's Home Robot Launch May Be Delayed to 2028
